Recombinant Human KIR2DL3/CD158b2 Fc Chimera Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

KIR2DL3 (2DL3, formerly NKAT2, designated CD158b2) is a 341 amino acid (aa) type I transmembrane glycoprotein that belongs to the human killer cell Ig‑like receptor (KIR) family of molecules (1, 2). KIRs are expressed on human CD56^dim NK cells and T cell subsets, and regulate effector functions in the innate immune system (1-3). KIRs are named for the number of Ig‑like domains (2D or 3D) in the extracellular domain (ECD), and whether they have long or short (L, S) cytoplasmic tails (1‑3). Individuals will express varying subsets of inhibiting and activating KIRs with varying polymorphisms (1, 4). Like other inhibiting KIRs, KIR2DL3 has two ITIM domains within its long tail that block activating receptor clustering (2). Within the ECD, KIR2DL3 shares very high aa sequence identity (98%) with KIR2DL2. The two segregate as alleles of the same gene; both recognize Asn80‑containing HLA‑C1 and, more weakly, Lys80‑containing C2 allotypes (1, 5). Extracellular aa identity is also high for KIR2DL1 (93%). The three molecules together recognize and inhibit NK cytotoxicity against cells expressing any HLA‑C allotype, allowing for self‑recognition (1‑3). Compared with KIR2DL2, KIR2DL3 shows lower avidity for HLA‑C1 ligands; when compared to KIR2DL1, KIR2DL3 has lower avidity but broader specificity for HLA-C1 ligands (1, 5, 6). Configurations of inhibiting and activating KIR can alter an individual’s susceptibility to viral and autoimmune diseases and leukemia (1‑3). For example, rheumatoid arthritis patients that are positive for KIR2DL3 and negative for KIR2DS3 have an earlier disease diagnosis (7).

We have publications tested in 1 confirmed species: Human.

We have publications tested in 2 applications: Binding Assay, Bioassay.

Showing Publications 1 - 4 of 4.

Publications using 2014-KR	Applications	Species
P Fittje, A Hœlzemer, WF Garcia-Bel, S Vollmers, A Niehrs, K Hagemann, G Martrus, C Körner, F Kirchhoff, D Sauter, M Altfeld HIV-1 Nef-mediated downregulation of CD155 results in viral restriction by KIR2DL5+ NK cells Oncogene, 2022-06-24;18(6):e1010572. 2022-06-24 [PMID: 35749424] (Bioassay, Human)	Bioassay	Human
L Thiruchelv, SE Hoelsbrekk, PC Saether, E Gyllensten, D Pende, S Fossum, MR Daws, E Dissen The Activating Human NK Cell Receptor KIR2DS2 Recognizes a ?2-Microglobulin-Independent Ligand on Cancer Cells J. Immunol, 2017-02-15;0(0):. 2017-02-15 [PMID: 28202613] (Binding Assay, Human)	Binding Assay	Human
Cifaldi L, Romania P, Falco M, Lorenzi S, Meazza R, Petrini S, Andreani M, Pende D, Locatelli F, Fruci D ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptors. Cancer Res, 2015-01-15;75(5):824-34. 2015-01-15 [PMID: 25592150] (Bioassay, Human)	Bioassay	Human
Cassidy S, Mukherjee S, Myint T, Mbiribindi B, North H, Traherne J, Mulder A, Claas F, Purbhoo M, Das J, Khakoo S Peptide selectivity discriminates NK cells from KIR2DL2- and KIR2DL3-positive individuals. Eur J Immunol, 2014-11-29;45(2):492-500. 2014-11-29 [PMID: 25359276] (Bioassay)	Bioassay

Array 2014-KR

• KIR2DL3/CD158b2 Antibodies
• KIR2DL3/CD158b2 Proteins and Enzyme